TDF and LdT in Immune-tolerant CHB Patients Awaiting Assisted Reproduction
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
Immune-tolerant patients with chronic hepatitis B (CHB) awaiting assisted reproduction (AR)
are required to initiate antiviral therapy due to laboratory safety. Additionally, rapid
virus elimination is suggested to faciliate timely performance of AR. However, no consensus
is reached regarding the antiviral therapy in this group. This study aimed to explore the
efficacy and safety of tenofovir (TDF) and telbivudine (LdT) in this population.